A report from FierceBiotech:
Roche provides update on leading late-stage pharmaceutical pipeline
New data on medicines with the potential to redefine standard of care highlighted at Investor event
Posted December 9, 2010
"Roche (SIX: RO, ROG; OTCQX: RHHBY) today will provide an update on its leading late-stage pipeline comprising twelve new molecular entities in key therapeutic areas. The London investor event will focus on major progress that has been achieved in recent months with Roche's late-stage pipeline assets in the areas of oncology and CNS, as well as on further development plans of these potential breakthrough medicines."
read the full report